1/6/14

Erectile Dysfunction: Phosphodiesterase-5 (PDE5) inhibition and the marketing of Levitra, Viagra and Cialis

G&G (12th Ed).
Section I
Chapter 3

1/13/14

Type 2 Diabetes:  Insulin resistance,  insulins and the marketing of Levemir and Lantus

G&G (12th Ed)
Section V
Chapter 43

1/20/14

MLK Day – No Class

1/27/14

Inflammatory Disorders:  Selective COX-2 inhibition and the marketing of Celebrex and VIOXX

G&G (12th Ed)
Section IV
Chapter 34

2/3/14

Multiple Sclerosis: T and B lymphocytes and the marketing of Tysabri, Gilenya and Aubagio

G&G (12th Ed)
Section IV
Chapter 35

2/10/14

Pneumococcal Pneumonia: Pneumococcal vaccine serotypes and the marketing of Prevenar 13 and Synflorix

G&G  (12 Ed)
Section VII
Chapter 48 & 53

2/17/14

Mid-Term Exam (In Class)

2/24/14

Cervical Cancer: Human papilloma virus (HPV) vaccine serotypes and the marketing of Cervarix (bivalent) and Gardasil (quadrivalent)

http://www.ncbi.nlm.nih.gov/pubmed/22920953
http://www.ncbi.nlm.nih.gov/pubmed/21819329
http://www.ncbi.nlm.nih.gov/pubmed/21415377
http://www.ncbi.nlm.nih.gov/pubmed/21166376

3/3/14

Overactive Bladder:  Anticholinergics and the marketing of Vesicare, Enablex, Ditropan and Sanctura

G&G (12th Ed)
Section II
Chapter 9